EE05111B1 - Interferoon-beetaga sulandatud valgud ja nende kasutamine - Google Patents

Interferoon-beetaga sulandatud valgud ja nende kasutamine

Info

Publication number
EE05111B1
EE05111B1 EEP200100223A EEP200100223A EE05111B1 EE 05111 B1 EE05111 B1 EE 05111B1 EE P200100223 A EEP200100223 A EE P200100223A EE P200100223 A EEP200100223 A EE P200100223A EE 05111 B1 EE05111 B1 EE 05111B1
Authority
EE
Estonia
Prior art keywords
beta
fusion proteins
interferon beta
interferon
polypeptide
Prior art date
Application number
EEP200100223A
Other languages
English (en)
Estonian (et)
Inventor
Whitty Adrian
Runkel Laura
Brickelmaier Margot
Hochman Paula
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200100223A publication Critical patent/EE200100223A/xx
Publication of EE05111B1 publication Critical patent/EE05111B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
EEP200100223A 1998-10-16 1999-10-15 Interferoon-beetaga sulandatud valgud ja nende kasutamine EE05111B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10449198P 1998-10-16 1998-10-16
US12023799P 1999-02-16 1999-02-16
PCT/US1999/024200 WO2000023472A2 (en) 1998-10-16 1999-10-15 Interferon-beta fusion proteins and uses

Publications (2)

Publication Number Publication Date
EE200100223A EE200100223A (et) 2002-06-17
EE05111B1 true EE05111B1 (et) 2008-12-15

Family

ID=26801613

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100223A EE05111B1 (et) 1998-10-16 1999-10-15 Interferoon-beetaga sulandatud valgud ja nende kasutamine

Country Status (28)

Country Link
US (3) US6800735B2 (de)
EP (1) EP1121382B9 (de)
JP (2) JP4761621B2 (de)
KR (1) KR100767649B1 (de)
CN (1) CN100480266C (de)
AT (1) ATE327254T1 (de)
AU (1) AU766190B2 (de)
BR (1) BR9915548A (de)
CA (1) CA2343094A1 (de)
CY (1) CY1105173T1 (de)
CZ (1) CZ300762B6 (de)
DE (1) DE69931507T2 (de)
DK (1) DK1121382T3 (de)
EA (1) EA005005B1 (de)
EE (1) EE05111B1 (de)
ES (1) ES2265693T3 (de)
HK (1) HK1042098B (de)
HU (1) HUP0200414A2 (de)
IL (2) IL142350A0 (de)
IS (1) IS5887A (de)
MX (1) MXPA01003790A (de)
NO (1) NO20011861L (de)
NZ (1) NZ510559A (de)
PL (1) PL200586B1 (de)
PT (1) PT1121382E (de)
SK (1) SK287491B6 (de)
TR (1) TR200101087T2 (de)
WO (1) WO2000023472A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245052T3 (es) * 1997-12-01 2005-12-16 Fang Fang Anticuerpos de recombinacion multivalentes destinados para el tratamiento de infecciones debidas al rinovirus humano (hrv).
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6697363B1 (en) 2000-06-28 2004-02-24 Alcatel Canada Inc. Method and apparatus for longest matching prefix determination in a communication network
WO2002036628A2 (en) * 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
EP1806144A3 (de) * 2000-12-06 2008-04-23 Laboratoires Serono SA Verwendung von SARP-1 zur Behandlung und/oder Vorbeugung von Scleroderma
DK1399568T3 (da) * 2001-02-01 2006-03-27 Hoffmann La Roche Fremgangsmåde til fremstilling af rekombinant trypsin
EP1366075B1 (de) 2001-02-27 2009-05-27 Maxygen Aps Neue interferon-beta-ähnliche moleküle
PL362870A1 (en) * 2001-03-15 2004-11-02 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity
JP2005522192A (ja) * 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
SI1471974T1 (sl) * 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
CA2492649A1 (en) * 2002-07-17 2004-01-22 Biogen Idec Ma Inc. Therapies for renal failure using interferon-.beta.
WO2004020468A2 (en) * 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
AU2003277088A1 (en) * 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
EP2204190A1 (de) * 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM-Produktion durch umgewandelte Zellen und Verfahren zur Quantifizierung der IgM-Produktion
AU2004271200A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
WO2005035574A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha IgM高濃度安定化溶液
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US20090214472A1 (en) * 2004-03-01 2009-08-27 Enzon Pharmaceuticals Inc. Interferon-beta polymer conjugates
WO2005120540A2 (en) * 2004-06-09 2005-12-22 Schering Aktiengesellschaft Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1845925B1 (de) 2005-01-12 2016-08-24 Biogen MA Inc. Verfahren zur verabreichung von interferon-beta
EP1933860A2 (de) 2005-09-01 2008-06-25 Ares Trading S.A. Behandlung von optikusneuritis
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
US8414897B1 (en) * 2006-10-02 2013-04-09 The Uab Research Foundation Pathway for Th-17 cell development and methods utilizing same
FR2907454B1 (fr) * 2006-10-18 2009-01-23 Biomethodes Sa Variants ameliores de l'interferon beta humain
CN101675071B (zh) 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
EP2190861A4 (de) 2007-08-22 2011-03-30 Univ California Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
US20100203009A1 (en) * 2007-10-02 2010-08-12 The Uab Research Foundation Pathway for Th-17 Cell Development and Methods Utilizing Same
WO2009053368A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
EP2300501B1 (de) 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. Polypeptidkomplex mit einem nicht-peptidyl-polymer mit drei funktionalen enden
EP2318029B1 (de) 2008-07-23 2017-11-01 Ambrx, Inc. Modifizierte bovine g-csf-polypeptide und ihre verwendung
EP3543256A1 (de) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modifizierte antikörperzusammensetzungen, verfahren zur herstellung und verwendung davon
US8399219B2 (en) * 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
DK2533634T3 (en) * 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
AR080993A1 (es) * 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
JP6145089B2 (ja) * 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法
IN2014CN02982A (de) * 2011-10-01 2015-07-03 Glytech Inc
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
SG11201503879QA (en) 2012-11-20 2015-06-29 Opko Biolog Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
KR102073748B1 (ko) 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
AU2014245917B2 (en) 2013-03-29 2017-09-28 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN106967175A (zh) * 2013-05-15 2017-07-21 复旦大学 长效干扰素及其制备方法和用途
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3083977B1 (de) 2013-12-20 2018-02-28 F. Hoffmann-La Roche AG Verbesserte rekombinante polypeptidherstellungsverfahren
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
KR102527180B1 (ko) 2014-12-10 2023-04-27 옵코 바이오로직스 리미티드 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법
KR102662956B1 (ko) 2015-06-19 2024-05-03 옵코 바이오로직스 리미티드 장기-작용성 응고 인자 및 그의 제조 방법
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
WO2017194783A1 (en) * 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP4303228B1 (de) 2016-07-11 2026-05-27 OPKO Biologics Ltd. Langwirkender gerinnungsfaktor vii und verfahren zur herstellung davon
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
US20230123454A1 (en) * 2020-01-23 2023-04-20 Genexine, Inc. Fusion protein comprising pd-l1 protein and use thereof
EP4126009A4 (de) * 2020-04-03 2024-04-17 The University of North Carolina at Chapel Hill Bindungsproteine zur verwendung gegen ace2-gerichtete viren
WO2021221470A1 (ko) * 2020-04-29 2021-11-04 (주) 제노팜 인터페론-베타 변이체와 항체가 융합된 재조합 단백질 및 이를 포함하는 약학 조성물
EP4176893A4 (de) * 2020-07-01 2024-10-23 Institute of Biophysics Chinese Academy of Sciences Konstruktion und anwendung einer fusionsproteinimpfstoffplattform
IL301246A (en) 2020-09-10 2023-05-01 Merck Patent Gmbh Treatment regimen with cladribine

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3359030A (en) * 1966-12-16 1967-12-19 Newman George Bumper guard assembly
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
WO1983002461A1 (en) * 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
GB8334102D0 (en) 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
EP0229108B1 (de) * 1985-06-26 1990-12-27 Cetus Corporation Solubilisierung von proteinen für pharmazeutische zusammensetzungen mittels polymerkonjugierung
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US4868802A (en) * 1986-07-28 1989-09-19 Kabushiki Kaisha Toshiba Magnetooptic recording and erasing head which performs biasing, tracking and focusing
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
AU4660789A (en) 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
EP0401384B1 (de) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemisch modifizierte granulocytenkolonie erregender faktor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993012145A1 (en) 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5255519A (en) 1992-08-14 1993-10-26 Millennium Technologies, Inc. Method and apparatus for increasing efficiency and productivity in a power generation cycle
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
DE69521880T2 (de) 1994-02-08 2002-01-03 Amgen Inc., Thousand Oaks Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
US5545723A (en) 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
JPH10510516A (ja) 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR0154850B1 (ko) * 1995-10-09 1998-10-15 김광호 바이씨모스 및 그의 제조방법
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
DE69936409T2 (de) 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
KR20020034181A (ko) 1999-08-27 2002-05-08 맥시겐 에이피에스 새로운 인터페론 베타-유사 분자
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US20080033818A1 (en) 2005-03-17 2008-02-07 Inc2 Webcom Ltd. Real time interactive response system and methods

Also Published As

Publication number Publication date
NO20011861D0 (no) 2001-04-11
IL142350A0 (en) 2002-03-10
US7527946B2 (en) 2009-05-05
EP1121382B9 (de) 2007-07-04
EE200100223A (et) 2002-06-17
TR200101087T2 (tr) 2001-09-21
SK287491B6 (sk) 2010-11-08
NZ510559A (en) 2003-12-19
IL142350A (en) 2007-07-04
AU1315800A (en) 2000-05-08
CN1333785A (zh) 2002-01-30
JP2002527100A (ja) 2002-08-27
WO2000023472A2 (en) 2000-04-27
EA005005B1 (ru) 2004-10-28
HK1042098B (zh) 2009-10-30
HK1042098A1 (zh) 2002-08-02
KR20010085932A (ko) 2001-09-07
WO2000023472A3 (en) 2000-08-31
DK1121382T3 (da) 2006-11-13
CN100480266C (zh) 2009-04-22
CY1105173T1 (el) 2010-03-03
MXPA01003790A (es) 2002-09-18
CA2343094A1 (en) 2000-04-27
PL347932A1 (en) 2002-04-22
US20020155547A1 (en) 2002-10-24
JP2010268810A (ja) 2010-12-02
KR100767649B1 (ko) 2007-10-17
BR9915548A (pt) 2001-08-14
CZ300762B6 (cs) 2009-08-05
EP1121382A2 (de) 2001-08-08
CZ20011330A3 (cs) 2001-09-12
SK5102001A3 (en) 2003-03-04
US6800735B2 (en) 2004-10-05
EP1121382B1 (de) 2006-05-24
NO20011861L (no) 2001-06-13
EA200100447A1 (ru) 2001-10-22
US20050214253A1 (en) 2005-09-29
US20090286958A1 (en) 2009-11-19
IS5887A (is) 2001-03-14
AU766190B2 (en) 2003-10-09
ES2265693T3 (es) 2007-02-16
DE69931507T2 (de) 2007-01-11
HUP0200414A2 (en) 2002-06-29
PT1121382E (pt) 2006-10-31
ATE327254T1 (de) 2006-06-15
DE69931507D1 (de) 2006-06-29
JP4761621B2 (ja) 2011-08-31
PL200586B1 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
EE200100223A (et) Interferoon-beetaga sulandatud valgud ja nende kasutamine
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
DE69933216D1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
TR199501669A1 (tr) Peptid ve proteinlerin aerosol formülasyonlari.
ATE103932T1 (de) Fusionsprotein bestehend aus gm-csf und il-3.
NZ503850A (en) April - a novel protein with growth effects
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
DK1490386T3 (da) Nyt polypeptid og nukleinsyrer kodende for dette
WO2001025438A3 (en) Ifn-alpha homologues
EP1739090A3 (de) Interferon Beta Fusions Proteine und deren Gebrauch
NO20005081D0 (no) Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav
GB2336844B (en) Anti-hiv peptides and proteins
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
DK0490383T3 (da) Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
DK0540560T3 (da) Ancrod-lignende proteiner, fremstilling og anvendelse deraf
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same
PL345267A1 (en) Recombinant human interferon beta-1a (ifn-beta-1a) formulation
MY114223A (en) Fusion proteins comprising gm-csf and il-3
DE69939345D1 (de) Neuartiges polypeptid und dessen kodierende nukleinsäuren
ATE404576T1 (de) Neuartiges polypeptid und dessen kodierende nukleinsäuren

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20121015